resignation

The Chairman, President, and CEO resigned yesterday, but the firm did not provide the reasons for his exit.

Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.

A member of Bruker's audit committee resigned earlier this month, leaving the firm short of the minimum number of committee members needed to satisfy a Nasdaq rule.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.